AQP2 and nephrotic syndrome: In the present study, we investigated the excretion of UE-AQP2 in nephrotic syndrome using rats treated with puromycin aminonucleoside (PAN), as well as the release of exosomal marker proteins, including tumor susceptibility gene 101 protein (TSG101) and ALG-2 interacting protein X (ALIX) [8,20].